Recon: Hims markets cheaper GLP-1 weight loss therapy in US; TrumpRx website to launch Thursday
Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.In Focus: US
- Telehealth provider Hims goes after Novo's weight loss pill with compounded version (Endpoints)
- Trump administration officials blocked FDA effort to fast-track review of psychedelic treatment (STAT)
- The FDA wants to rein in drug ads. On Super Bowl Sunday, it will be business as usual (STAT)
- New PBM law could open door to direct sales between employers, drugmakers (STAT)
- TrumpRx Is Set to Go Live on Thursday (NYTimes)
- TrumpRx has a fundamental flaw (STAT)
- Novo Slump Is No Buy-the-Dip Moment for Top Danish Investor (Bloomberg)
- CDRH Highlights Harmonization Progress In International Assessment Report (MedTech Insight)
- Could Higher UK Drug Prices Trigger A Domino Effect Elsewhere? (Pink Sheet)
- CEPI, Korea Discuss Future Of AI-Based Global Health Cooperation (Pink Sheet)
- Novo Nordisk CEO says Hims $49 compounded Wegovy pill a 'waste' of money (Reuters)
- US FDA Review Team Split On Amgen’s Tavneos Years Before Withdrawal Request (Pink Sheet)
- Nektar Therapeutics is trying to stage a comeback. But a big test awaits (STAT)
- A sneak peek of pharma’s Super Bowl ads: GLP-1s, tight ends, and more (STAT)
- Dispute between Corcept Therapeutics, FDA runs deep (STAT)
- What Eikon’s modest IPO says about the future of big-money, big-name biotech (Endpoints)
- Bristol Myers draws pipeline excitement as several data readouts near (Endpoints)
- Bayer’s next-gen blood thinner reduced ischemic strokes by 26% in Phase 3 win (Endpoints)
- Flagship’s Generate files for an IPO in key test for the AI bio field (Endpoints)
- GLP-1s and the Super Bowl (Endpoints)
- Angitia gets $130M Series D for pipeline of musculoskeletal drugs (Endpoints)
- Goldman, Blackstone to Fund $976 Million Loan for Pharma Buyout (Bloomberg)
- Boston Scientific continues to see electrophysiology success despite slowdown in growth (MedTech Dive)
- J&J corrects Impella heart pumps over issue linked to 22 serious injuries (MedTech Dive)
- Medtronic wins expanded FDA label for 780G insulin pump (MedTech Dive)
- Prices rise at surgery centers acquired by Optum: study (MedTech Dive)
- Weight-loss drugs, soft-drink tax curtail sugar consumption (Reuters)
- UK says infant formula contamination could have affected 36 babies (Reuters)
- We helped create Medicare Advantage. Here’s how to fix it (STAT)
- STAT Plus:Inside HHS’ anti-fraud efforts: An aggressive crackdown sweeps up mainly Democratic-led states (STAT)
- FTC settles insulin suit with Express Scripts, with wider implications attached (Endpoints)
- Genetic testing takes greater share of Medicare Part B test spending: OIG (MedTech Dive)
A story’s inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.
